In The Spotlight
DDNews Cancer Research Exclusive
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
(Photo credit: University of Toronto)
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
Orphan diseases are seeing increased attention in recent years due to the appeal of markets with low competition, but rare oncology types are another beast entirely
A roundup of clinical trial startups and initial breakthroughs
PPD Biotech will manage Treos Bio's first-in-human study of its lead therapeutic cancer vaccine for metastatic colorectal cancer
Salk researchers says decisions in DNA repair are aided by a microprotein
ANGLE and QIAGEN form collaboration aimed at liquid biopsies for breast and prostate cancer
Dako PD-L1 IHC 28-8 pharmDx approved for two new indications
New data is available from Sysmex Inostics, a subsidiary of Sysmex Corp., regarding a real-world prospective evaluation of its OncoBEAM RAS CRC test for routine clinical use in hospital laboratories.
NanOlogy platform takes chemo directly to the tumor
(Photo credit: NCI, NIH)
The latest Annual Report to the Nation shares that cancer survival rates are rising, while incidence and death rates are on a downward trend
by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

by Dr. Brad Thompson, Oncolytics
During these heady and still-early days in the age of clinical studies involving immunotherapy, it is useful to ponder some of the outstanding questions these studies raise

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.